DURGA-6

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Aug 1, 2026 → Sep 27, 2026

Cited window

Aug 3, 2026 → Sep 23, 2026

Retrieved

Oct 30, 2026

Title

A Phase III, Open-label, Multicentre, Randomised Study Comparing Consolidation Treatment With AZD0120, an Autologous Dual Targeting Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Versus Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (TE NDMM) (DURGA-6)

Registry

NCT07735637

Study IDs

D8316C00001 · AZD0120 (AstraZeneca)

Sponsor

AstraZeneca

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

750 estimated

Registered

2026-07-30

Start

2026-09-24 actual

Primary completion

2028-11-02 estimated

Primary endpoint

Progression-Free Survival (PFS)

Interventions

5 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some clinician views in the sources used in this report are not yet captured as evidence in this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –76 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition provide perspectives from a small set of conversations, not a representative measure of HCP opinion. Podcast and video versions of the ONS session must not be counted as independent support.
• –No publication of results for NCT07735637 was found, and no protocol was available among the sources reviewed. The report cannot establish comparative efficacy, trial-specific safety or detailed protocol requirements.
• –Earlier Chinese frontline findings include both transplant-eligible and transplant-ineligible patients. Their favorable interpretation does not establish benefit over ASCT in DURGA-6.
• –Several treatment-choice statements do not name DURGA-6. They are contextual views on the relevant clinical decision, not direct evaluations of the trial's outcomes or conduct.
• –Some podcast remarks about future treatment roles do not identify who spoke. Those passages remain unnamed and are not treated as additional independent views.
• –Discussion using unnamed trial references, alternative terminology or different transcriptions may be missing, and some additional X material was not fully assessed.
• –No exact AZD0120 product label was located, and the broader regulatory review was incomplete. General CAR-T practices in these discussions cannot be treated as AZD0120 prescribing instructions.
• –The safety discussion is selective: the institutional policy on prophylactic tocilizumab and concerns about prolonged cytopenias, clonal marrow changes and secondary malignancies are not characterized here. This limits conclusions about preventive care and long-term safety.
• –Not yet captured in this edition: a view on geographic CAR T access barriers and developing CAR T capacity at transplant centers.

How reports are built and checked: Methods.

Last checked for new commentary Oct 30, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "DURGA-6" (NCT07735637), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "durga-6-07735637". If you cannot make requests, read https://www.erudio.com/reports/durga-6-nct07735637.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07735637", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07735637 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/durga-6-nct07735637.json
curl https://www.erudio.com/reports/durga-6-nct07735637.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "durga-6-07735637" })